Review of Myopia Management

1 week ago | reviewofmm.com | Kristen Dalli

April 16, 2025PARIS, France — At the 2025 China Optometry & Ophthalmology Conference (COOC), EssilorLuxottica shared the six-year data from the clinical trial on its Stellest lenses. The results underscore the significant and sustained impact of Essilor Stellest lenses in controlling myopia progression, offering valuable insights into strategies for addressing the global myopia epidemic. The findings were presented for the first time during a dedicated satellite session at COOC 2025 by Prof.

1 week ago | reviewofmm.com | Kristen Dalli

April 1, 2025On April 1, Kevin Chan, OD, MS, FAAO, and Ashley Tucker, OD, FAAO, FSLS, become the new medical co-editors at Review of Myopia Management. They take the reins from Dwight Akerman, OD, MBA, FAAO, Dipl AAO, FBCLA, FIACLE, the founding chief medical editor of Review of Myopia Management, who becomes the chief medical editor emeritus. The two co-editors are both active in myopia management in their respective practices.

1 month ago | reviewofmm.com | Kristen Dalli

March 17, 2025VAUGHN, Ontario, Canada — Bausch + Lomb has officially launched its orthokeratology lens, Arise, in the United States. The lens fitting system uses intelligent, cloud-based technology to streamline the OrthoK lens design process. Arise seamlessly syncs directly with topographers — diagnostic tools that capture 3D images of the eye — to create precise lens designs in seconds to treat myopia.

1 month ago | reviewofmm.com | Gonzalo Carracedo |Kristen Dalli

sponsored contentMarch 17, 2025Astigmatism correction in myopic patients has long been a challenge, but recent clinical findings offer promising solutions. Review of Myopia Management sat down with Dr. Ashley Tuan, Chief Medical Officer of Visioneering Technologies Inc. (VTI), to discuss groundbreaking insights from a clinical trial conducted by Professor Gonzalo Carracedo of the Universidad Complutense de Madrid.

1 month ago | reviewofmm.com | Kristen Dalli

March 11, 2025DEL MAR, Calif. — The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for Sydnexis’ SYD-101 for myopia management. The agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 23, 2025. If approved, SYD-101 would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States.